MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.

Recent studies in human and murine systems suggest a central role for CD4+ T cells in initiating, effecting and maintaining anti-tumor immunity. Characterization of the tumor-associated antigens recognized by CD4+ T cells may prove critical to the success of cancer immunotherapy strategies.

[1]  D. Pardoll.  A new look for the 1990s , 1994, Nature.

[2]  E. Thorsby,et al.  p21‐ras‐peptide‐specific T‐cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly → Asp) , 2007, International journal of cancer.

[3]  A. McAdam,et al.  Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. , 1993, Cancer research.

[4]  K. Okuno,et al.  FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens , 1989, The Journal of experimental medicine.

[5]  S. Rosenberg,et al.  CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens. , 1994, Cancer research.

[6]  G. Forni,et al.  Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. , 1992, Journal of immunology.

[7]  A. Asher,et al.  Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. , 1993, Journal of immunology.

[8]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[9]  P. Greenberg,et al.  Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells , 1985, The Journal of experimental medicine.

[10]  S. Rosenberg,et al.  Murine epidermal Langerhans cells and splenic dendritic cells present tumor‐associated antigens to primed T cells , 1994, European journal of immunology.

[11]  S. Rosenberg,et al.  Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. , 1994, Cancer research.

[12]  P. Coulie,et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.

[13]  P. Greenberg,et al.  Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. , 1986, Journal of immunology.

[14]  S. Rosenberg,et al.  Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation. , 1993, Blood.

[15]  G. Forni,et al.  Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. , 1990, Journal of immunology.

[16]  J. Wharton,et al.  Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. , 1993, Cellular immunology.

[17]  G. Riethmüller,et al.  Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. , 1993, Journal of immunology.

[18]  P. Leder,et al.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.

[19]  D. Pardoll,et al.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.

[20]  P. Greenberg,et al.  An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues , 1993, The Journal of experimental medicine.

[21]  S. Rosenberg,et al.  Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. , 1991, Journal of immunology.

[22]  S. Rosenberg,et al.  Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans. , 1990, Important advances in oncology.

[23]  S. Rosenberg,et al.  Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cells , 1994, International journal of cancer.

[24]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[25]  H. Ploegh,et al.  Isolation and characterization of the intracellular MHC class II compartment , 1994, Nature.

[26]  T. Eberlein,et al.  Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. , 1994, Journal of immunology.

[27]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Gilboa,et al.  The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. , 1994, Journal of immunology.

[29]  M. Moser,et al.  Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo , 1994, European journal of immunology.

[30]  S. Rosenberg,et al.  Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.